In non-endemic countries, there is little evidence on the clinical importance of Epstein-Barr virus (EBV) indicators for nasopharyngeal carcinoma NPC diagnosis and monitoring. Due to the low prevalence of NPC in non-endemic countries, it was difficult to create a representative group of patients to study this issue. Furthermore, due to geographic and ethnic diversity, NPC cases are frequently classified into physically distinct tumour categories. Because viral and serological markers reflect the various biological events that occur during the progression of NPC, it is critical to compare their clinical utility in the context of various disease presentations. endemic populations from endemic areas We investigated the clinical importance of two EBV indicators (serological and molecular) in a large group (96 cases) of Russian patients with undifferentiated non-keratinizing carcinoma of the nasopharyngeal type (UNPC). It has been demonstrated that increased IgA/VCA antibody titers on admission, while useful markers for primary UNPC diagnosis, do not allow for effective assessment of patients' status after treatment. Unlike EBV serology, plasma EBV DNA load has been demonstrated to be a useful marker for clinical evaluation of UNPC patient status, such as remission and relapse. The concentration of viral DNA was also found to be connected to the overall survival of UNPC patients. The proposed study, which was conducted on UNPC patients from a non-endemic region, revealed for the first time a direct correlation between IgG/IgA antibody titers to EBV virus capsid antigen (VCA) and plasma EBV DNA load levels, as well as the lack of such a correlation between plasma EBV DNA burden and EBV serological responses. The combination of plasma EBV DNA load and EBV-specific antibody titers has also been shown to be a reliable method to UNPC diagnosis, illness monitoring, and therapy response assessment.
Author (s) Details
Ksenia Smirnova
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; 24 Kashirskoe Shosse, 115478 Moscow, Russia and Pirogov National Research Medical University, Ministry of Health of Russia; 1 Ostrovityanova St., 117997Moscow, Russia.
Natalia Senyuta
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; 24 Kashirskoe Shosse, 115478 Moscow, Russia.
Anatoly Lichtenstein
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; 24 Kashirskoe Shosse, 115478 Moscow, Russia.
Vladimir Gurtsevitch
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; 24 Kashirskoe Shosse, 115478 Moscow, Russia.
View Book :- https://stm.bookpi.org/IDHR-V1/article/view/2156
No comments:
Post a Comment